Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acetylcysteine - Zambon

Drug Profile

Acetylcysteine - Zambon

Alternative Names: Fluimucil; Flumil; N-acetylcysteine - Zambon; NAC - Zambon; NSC 111180; Rinofluimucil

Latest Information Update: 09 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zambon Group SpA
  • Developer Elder Pharmaceuticals; Inpharzam Ricerche S.A.; Sermmitr; Zambon Company SpA
  • Class Antibronchitics; Antidotes; Expectorants; Reducing agents; Small molecules; Sulfur amino acids
  • Mechanism of Action Free radical inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary fibrosis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease; Common cold; Poisoning; Respiratory tract disorders
  • Discontinued HIV infections; Pulmonary fibrosis; Renal failure

Most Recent Events

  • 11 Nov 2019 Zambon SpA initiates a phase I trial in Respiratory tract disorders (In volunteers) in China (IV, Infusion) (NCT03881163)
  • 25 Jun 2019 Zambon SpA initiates a phase III trial for Respiratory tract disorers in China , (NCT03843541)
  • 27 Mar 2019 Zambon SpA plans a phase I trial for Respiratory Tract Disorders in China (IV) (NCT03881163)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top